

10 Mar 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Bayer won't split, for now; Pfizer's next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS's CEO gives his views on India.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 8 March 2024, including: [Bayer AG](#) won't split, for now; [Pfizer Inc.](#)'s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and [Bristol Myers Squibb Company](#)'s CEO gives his views on India.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Bayer Boss Rules Out Divisions Split For Now](#)" - Scrip, 5 Mar, 2024.)

(Also see "[A Sneak Peak At Pfizer's Next-Generation ADC Pipeline](#)" - Scrip, 1 Mar, 2024.)

(Also see "[In Investing, Oncology Is Still King, But Other Indications Joining The Royal Court](#)" - Scrip, 1 Mar, 2024.)

(Also see "[Say Goodbye To NASH And Hello To MASH](#)" - Scrip, 6 Mar, 2024.)

(Also see "[*BMS' Boerner Bets On AI-Driven R&D In India, Points To Potential For MS, Lupus Drugs*](#)" - Scrip, 4 Mar, 2024.)

[Click here to explore this interactive content online](#) ✎